The present disclosure provides methods of treating polycystic ovary syndrome (PCOS) with tetrahydro-iso-alpha acid (THIAA) derivatives and substantially enantiomerically pure compositions and pharmaceutical formulations thereof, in particular KDT500 and KDT501.